Drug Trial Radar · NCT07040930
Assessment of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China.
Last checked: Nov 20, 2026Latest source record: Aug 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Aug 1, 2025
Primary completion
Jul 5, 2026
Study completion Sep 20, 2026
Sponsor
- Lead sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the safety, tolerability, PK and PD of multiple subcutaneous injections of GenSci120 in a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase Ib trial involving healthy adult participants.
Conditions
- Rheumatoid Arthritis
Interventions
GenSci120Drug
a total of 3 doses of the investigational medicinal product (IMP) SC every four weeks (Q4W) at the planned dose level
PlaceboDrug
a total of 3 doses of the investigational medicinal product (IMP) SC every four weeks (Q4W) at the planned dose level
Primary outcomes
What the sponsor says the trial is designed to measure.
- TEAEsTime frame: 169 days
- SAEsTime frame: 169 days
- CSfadfTime frame: 169 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.